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A b s tra c t
Background: The treatment of patients with haematological malignancies by means of 
haematopoietic stem cell transplantation (HSCT) is often accompanied by life threatening 
infections. W ith emerging antimicrobial resistance there is an increased need for new agents, with 
a beneficial safety profile. Therefore we evaluated the safety of the promising new antimicrobial 
peptide human lactoferrrin l-ll (hLFl-l l)  in healthy volunteers and patients.
Methods: W e  undertook a sequential, randomised, double-blind, placebo-controlled study using 
ascending single (0.005, 0.05, 0.5, 5 mg) and multiple intravenous doses (0.5, 5 mg) in healthy 
volunteers, and open-label, single intravenous 5 mg doses in autologous HSCT recipients.
Results: Single and multiple doses of hLFl-ll were tolerable up to 5 mg intravenously in healthy 
volunteers, while 5 mg single dose was tolerable in patients. Elevations in transaminases possibly 
related to treatment were reversible and not serious.
Conclusion: The new antimicrobial hLFl-l l is well tolerated in healthy volunteers with repeated 
daily doses up to 5 mg. The side-effect profile is very favourable for an antimicrobial, the only 
undesirable effect being a possible elevation of transaminases, which may be related to hLFl-ll 
although the current data do not allow conclusive interpretation of treatment relationship. A  lower 
dose is recommended for the forthcoming multiple dosing studies in HSCT patients.
T ria l registration: ClinicalTrials.gov: nct00509938.
Background
The treatment of patients with haematological malignan­
cies with haematopoietic stem cell transplantation 
(HSCT) is often accompanied by life threatening compli­
cations as a result of the damage caused by the condition­
ing regimens to the mucosal barrier, and the innate and
adaptive, humoral and cellular immune defences [1-3]. 
Despite many advances in supportive care, transplanta­
tion-related morbidity and mortality due to bacterial and 
fungal infections and uncontrolled inflammation remains 
high [4,5]. A troublesome fact is the increasing resistance 
against several im portant antimicrobial drugs including
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quinolones, azoles and cephalosporins, making control 
of bacterial and fUngal infections in HSCT a difficult task 
[6-8]. Therefore, the discovery of a broad array of naturally 
occurring antimicrobial peptides (AMPs) is interesting, 
although few AMPs have been studied so far and even less 
have been studied in clinical settings [9-11].
Human lactoferrin is a natural defence protein present in 
body fluids and secretions as well as neutrophils [12, 13], 
and has pleiotropic functions including broad spectrum 
antimicrobial activity, antitumour activity, regulation of 
cell growth and differentiation, and m odulation of 
inflammatory, humoral and cellular immune responses 
[14-17]. Levels of lactoferrin are decreased following 
HSCT [18], contributing to the overall immune defi­
ciency. Correcting this deficit might ameliorate immunity 
in HSCT recipients [19].
Human lactoferrin 1-11 (hLF1-11) is a lactoferrin deriva­
tive being developed for the treatment of bacterial and 
fungal infections in HSCT recipients. It contains the N-ter- 
minal moiety of hLF, consisting of 11 amino acids, that is 
essential for the antimicrobial and anti-inflammatory 
activity [14,15]. Preclinical studies have shown promising 
antimicrobial activity even in the setting of immunodefi­
ciency justifying further investigation for clinical applica­
tion [20-24]. Being a derivative of a 'natural' hum an 
protein, hLF1-11 might have the advantage of fewer side 
effects and less formation of antibodies and antimicrobial 
resistance, especially since antimicrobial peptides are 
unlikely to induce resistance because of the evolutionary 
difficulty in changing bacterial membrane structure [11].
We report on the first three studies conducted in humans 
with ascending doses of hLF1-11 in healthy volunteers 
and in patients receiving autologous HSCT following con­
ditioning with high-dose melphalan (HDM) for multiple 
myeloma or lymphoplasmocytic lymphoma.
M ethods  
Study design
The 3 studies were conducted sequentially and included a 
total of 56 subjects (placebo: 12; hLF1-11: 44) as follows. 
Study 1: single intravenous administration of ascending 
hLF1-11 doses (0.005, 0.05, 0.5 and 5 mg) in healthy vol­
unteers; study 2: multiple intravenous administration of 
two ascending hLF1-11 doses (0.5 and 5 mg daily for 5 
days) in healthy volunteers; study 3: single intravenous 
administration of a fixed hLF1-11 dose (5 mg) in patients 
undergoing an autologous HSCT (Table 1, Additional file 
1).
Blinding and subject selection
Studies 1 and 2 were conducted in healthy volunteers, 
both were randomised, placebo controlled, enrolled 48 
volunteers in total (placebo: 12; antimicrobial peptide 
(AP): 36) (Table 1) and were conducted at the Phase-I 
Clinical Pharmacology Unit, Xendo Drug Development 
BV, Groningen, The Netherlands, with prior approval by 
the appropriate Institutional Review Board (IRB). Entry 
criteria were similar for studies 1 and 2, namely subjects 
considered healthy during medical screening by a quali­
fied physician, medical history, physical examination, 
vital signs, blood and urine evaluations, and 12-lead elec­
trocardiogram (ECG). Age and body mass index (BMI) 
entry criteria were 18 to 45 years (study 1) and 1 to 65 
years (study 2), and 18 to 30 kg/m2 (study 1) and 18 to 28 
kg/m2 (study 2), respectively. All volunteers provided 
written informed consent and the studies were conducted 
in compliance with current Guidelines on Good Clinical 
Practice [25]. Enrolment took place between March and 
April 2005 (study 1) and August and September 2005 
(study 2). The aims of both studies were to evaluate the 
safety, tolerability and pharmacodynamics of intravenous 
administration of hLF1-11. Safety parameters were 
adverse events, vital signs, changes in ECG, haematology, 
clinical chemistry, urinalysis and immunogenicity. Phar­
Table 1: En try  dem ographics and dosing schedule.
Subjects Mean age Mean 
(SD ), years height
(SD ), cm
Mean 
weight 
(S D ), kg
Mean BM I 
(S D ), kg/ 
m 2
Male/ 
fem ale, n
Dosing Dose
(m g)
Placebo, n hLF  1-11, n A ll, n
Study 1 Healthy 24 (5) 185 (6) 79 (9) 23 (3) 32/0 Single 0.005 2 6 8
volunteers
0.05 2 6 8
0.5 2 6 8
5.0 2 6 8
Study 2 Healthy 32 (12) 183 (7) 78 (12) 23 (3) 16/0 Multiple 0.5 2 6 8
volunteers
5.0 2 6 8
Study 3 HSCT 53 (8) 178 (7) 78 (14) 24 (3) 7/1 Single 5.0 - 8 8
patients
12 44 56
BMI = body mass index; hLF, human lactoferrin; HSCT = haematopoietic stem cell transplant.
Page 2 of 8
(page number not for citation purposes)
BMC Medicine 2009, 7:44 http://www.biomedcentral.eom/1741-7015/7/44
macodynamics evaluations were conducted during multi­
ple dosing (study 2) at baseline, days 1 and 5: cytokine 
release (interleukin (IL)6, IL10, and tum our necrosis fac­
tor (TNF)a) after ex vivo stimulation with lipopolysaccha- 
ride (LPS) endotoxin in whole blood.
Study 3 was conducted in autologous HSCT recipients. 
The study was open, and enrolled eight patients (Table 1) 
between March and October 2006 at the Department of 
Haematology, Radboud University Nijmegen Medical 
Centre, The Netherlands, with prior approval by the hos­
pital's IRB. Study conduct was in compliance with current 
Guidelines on Good Clinical Practice [25]. Entry criteria 
were males/females aged 18 years or older who were 
admitted to hospital for autologous HSCT after myeloab- 
lative therapy with HDM for multiple myeloma or lym- 
phoplasmocytic lymphoma, BMI <30 kg/m2, without 
serious other pathologies, or history of hepatitis B or C, or 
HIV infection. The aim of study 3 was to evaluate the 
safety and tolerability of hLF1-11 given as a single intrave­
nous administration (5 mg) on the day of transplantation. 
Safety parameters were adverse events, vital signs, changes 
in  ECG, haematology, clinical chemistry, urinalysis, and 
immunogenicity. Safety and tolerability were evaluated by 
adverse event reporting, vital signs, changes in  ECG, hae­
matology, clinical chemistry, and urinalysis. Adverse 
events were graded according the to the Common Termi­
nology Criteria for Adverse Events (CTCv3.0, National 
Cancer Institute, Bethesda, MD, USA) [26].
Blinding in  studies 1 and 2 was assured by central alloca­
tion of randomisation codes in sealed envelopes, audited 
on completion of each study and by supply of study med­
ication in  indistinguishable form.
For the pharmacodynamics evaluations, cytokine meas­
urements were analysed in  study 2 using validated assays 
for each cytokine once prior to dosing and at six time­
points post dosing (5 min, 30 min, 2 h, 4 h, 8 h, and 24 
h) on days 1 and 5, while antibodies against hLF1-11 were 
measured in all three studies as specific IgG anti-HLF1-11 
and IgE anti-hLF1-11 once prior to dosing and at three 
timepoints post dosing (days 2 and 3, 5 to 8, and 14 and 
15) by validated enzyme-linked im munosorbent assay 
(ELISA), centrally by Xendo Biotech Centre, Groningen, 
The Netherlands.
Study medication (active and placebo) was supplied by 
AM-Pharma BV (Bunnik, The Netherlands) as lyophilised 
powder for solution in normal saline (0.9% NaCl solu­
tion) according to dose.
Statistics, assignment and analysis
Treatment allocation was sequential in all studies, with 
randomisation lists issued as single blocks of eight (two 
placebo, six active) for studies 1 and 2, while there was no
randomisation in study 3. The intention to treat (ITT) 
population for safety evaluations was defined in  all stud­
ies as all randomised subjects who received any medica­
tion. Data for studies 1 and 2 were analysed by Xendo 
Drug Development, Groningen, using SAS version 8.2 
(SAS, Cary, NC, USA) and for study 3 by CRM Biometrics 
GmBH (Bonn, Germany), who also checked the databases 
for the other two studies. Means, standard deviations, 
medians, ranges, upper and lower quartiles were calcu­
lated, and parameters were listed by subject, summarised 
and evaluated using descriptive statistics.
Results
Subject characteristics and progress through studies
Demographic data for all three studies at entry are dis­
played in  Table 1, with pathological characteristics of 
patients in  study 3 presented in  Table 2 . One volunteer in  
study 2, originally allocated to the placebo group (multi­
ple dosing) received one dose of active drug (5 mg) on day
4 due to an administrative error, and his safety data were 
computed in  the active group. All other subjects in  the 
studies received study medication as planned and yielded 
complete datasets for safety and other analyses.
Safety and tolerability results
The main adverse events from the safety evaluations are 
presented in  Table 3 for studies 1 and 2, and Table 4 for 
study 3. Overall, intravenous administration of hLF1-11 
did not raise safety concerns in  either volunteers or 
patients. During single dosing in  volunteers, all events 
blindly rated as possibly related to treatment were 
reported once and occurred on placebo and the lowest 
hLF1-11 dose (0.005 mg), none being reported on the two 
higher doses. During multiple dosing, the commonest 
reported events on hLF1-11 were elevations in liver 
enzymes (alanine aminotransferase (ALT) and aspartate 
aminotransferase (AST)), which were below twice the 
upper level of the normal range (ULN; 40 U/l for ALT; 45 
U/l for AST) in one volunteer on 0.05 mg and in two vol­
unteers on 5 mg. The third event was below three times 
the ULN. Detailed analysis of daily measurements of liver 
enzymes, regardless of levels being reported as adverse 
events, recorded enzymes levels above the ULN in 1/2 pla­
cebo volunteers and in 3/6 volunteers on 0.05 mg dose, 
while levels above the ULN were recorded in 6/7 volun­
teers on 5 mg. All bu t one of the daily measurements were 
below twice the ULN (one ALT measurement was 127 U/ 
l on day 6; 5 mg dose). All levels were in the normal range 
within 7 days thereafter.
In HSCT recipients after conditioning with HDM, as 
expected, several events were recorded, ranging from 5 to 
35 events per patient (Table 4). Four serious adverse 
events (SAEs) were reported, none of which were consid­
ered to be related to hLF1-11, while four non-serious 
events were reported in  one patient, considered possibly
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Table 2: Disease characteristics of patients who underwent haem atopoietic stem cell transplant (H S C T ).
Pa tien t no. A g e  (years) G ender Diagnosis,
stagea
Parapro te in
type
Bence-Jones P r io r
tre a tm en t
S ta tu sb Melphalan 
dose (mg/kg)
SC00I 61 M Multiple 
myeloma, III-A
IgG K Not present VAD, CAD Partial
response
3.92
SC002 62 F Multiple 
myeloma, III-A
IgG K Present VAD, CAD Progressive
disease
5.61
SC003 50 M Multiple 
myeloma, III-A
Light chain K Present VAD, CAD Minimal
response
5.19
SC004 55 M Multiple 
myeloma, III-A
IgG K, light 
chain K
Not present VAD, CAD Partial
response
5.13
SC005 45 M Multiple 
myeloma, III-A
Light chain K Present PAD, CAD Partial
response
6.25
SC006 39 M Multiple 
myeloma, III-B
IgG K Not present VAD, CAD Minimal
response
4.37
SC007 54 M Multiple 
myeloma, II-A
IgG K Not present Thalidomide,
dexamethasone,
CAD
Stable disease 5.07
SC008 6I M Lymphoplasmoc 
ytic lymphoma, 
IV-A
IgG K, light 
chain K
Present VAD, CAD Minimal
response
5.13
“Staging by Durie and Salmon criteria [41]; bstatus after previous treatment by International Bone Marrow Transplant Registry and Autologous 
Blood, and Marrow Transplant Registry criteria [42].
ALT = alanine aminotransferase; AST = aspartate aminotransferase; C A D  = cyclophosphamide, adriamycin, dexamethasone; PAD = bortezomib, 
adriamycin, dexamethasone; VAD  = vincristine, adriamycin, dexamethasone.
related to hLF1-11, and none were reported for the 
remaining seven patients.
Other clinical laboratory tests (haematology, biochemis­
try, and urinalysis) did not suggest any treatment-related 
abnormalities in any of the three studies. No abnormali­
ties in coagulation tests were seen. Haemodynamic tests 
(blood pressure, heart rate) and 12-lead ECGs (including 
QT interval) did not yield any treatment-related effects. 
None of the HSCT recipients developed signs of haemol­
ysis or unexpected cytopoenias and no abnormalities 
regarding engraftment were seen.
Pharm acodynam ic evaluations
There were no changes in any of the pharmacodynamic 
evaluations in volunteers during single or multiple dosing 
or in patients after single dosing. Cytokine measurements 
in study 2 (healthy volunteers) showed high variability 
intraindividually and interindividually. Levels of IL10 
were undetectable in all samples. Release of IL6 and TNFa 
on LPS stimulation seemed attenuated with 0.5 and 5 mg; 
however this was neither clinically nor statistically signif­
icant. No antibodies against hLF1-11 were detected (IgG 
anti-hLF1-11 or IgE anti-hLF1-11) in volunteers or 
patients.
Discussion
Bacterial pathogens account for most infections occurring 
shortly after transplantation during neutropaenia, when 
mucosal barrier injury is most pronounced. Whilst most 
patients receive standard antibacterial prophylaxis with
fluoroquinolones, the majority of infections are caused by 
Gram-positive bacteria (65% to 75%), mainly viridans 
group streptococci and coagulase-negative staphylococci 
as observed in all our patients, and in a minority by Gram­
negative pathogens, mostly Enterobacteriaecae [27]. The 
incidence of fungal infections also remains relatively high 
affecting up to 15% in allogeneic HSCT, with Candida spe­
cies and Aspergillus fum igatus predominating [27]. Lactof- 
errin or derivatives may prove to be a promising versatile 
class of agents for managing infectious complications that 
arise from HSCT, because of their broad antimicrobial 
activity especially in the context of emerging antimicro­
bial resistance to currently used antimicrobial agents. 
Additionally, immune modulating and anti-inflamma­
tory properties might attenuate mucosal barrier injury and 
graft versus host disease in HSCT, although for now this 
remains speculative [19].
The N-terminal moiety of hLF, in particular the first five 
amino acids (Gly-Arg-Arg-Arg-Arg), has a high cationic 
charge allowing binding to negatively charged molecules 
including microbial products such as lipopolysaccharide 
(LPS) and CpG motifs of bacterial DNA (CpG-DNA) 
[28,29]. These interactions result in microbial cell wall 
disruption and direct microbial killing as a result [30]. 
Additionally, indirect antimicrobial activity is seen 
through the intermediary of cells mainly phagocytes cells 
(polymorphonuclear cells, macrophages) probably as 
result of opsonisation and probably other not yet fully 
determined mechanisms [31-33]. Anti-inflammatory and
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P lacebo, n hLFI-11, 0.005 mg, n h L F I- I I ,  0.05 mg, n h L F I- I I ,  0.5 mg, n h L F I- I I ,  5 mg, n
(% ) (% ) (% ) (% ) (% )
Study 1 (single dosing):
Subjects per group 8 (100) 6 (100) 6 (100) 6 (100) 6 (100)
Diarrhoea - 1 (16.7) - - -
Dizziness - - - - 1 (16.7)
Epistaxis 1 (12.5) - - - -
Feeling cold - 1 (16.7) - - -
Flatulence - - - - 1 (16.7)
Headache 1 (12.5) 1 (16.7) - - 1 (16.7)
Increased appetite 1 (12.5) - - - -
Phlebitis - - - - 1 (16.7)
Purpura - - - - 1 (16.7)
Somnolence 1 (12.5) - - - 1 (16.7)
Study 2 (multiple
dosing):
Subjects per group 3a (100) 6 (100) 7a (100)
ALT increase - 2 (33.3) 3 (42.9)
AST increase - - 1 (14.3)
Dry skin 1 (33.3) 1 (16.7) -
Hyperhydrosis - 1 (16.7) -
Injection site 1 (33.3) - -
erythaema
Injection site pain 1 (33.3) - -
Injection site reaction - 2 (33.3) 1 (14.3)
Malaise - 1 (16.7) -
Nausea - 1 (16.7) -
All listed events were rated blindly as possibly related to treatment.
aOne subject in the placebo group (no. 01 6) received one dose of hLF 1-11 5 mg (day 4) due to administrative error, therefore events were
computed in the 5 mg group.
ALT = alanine aminotransferase; AST = aspartate aminotransferase.
immune-modulatory properties have also been largely 
related to N-terminal moiety of hLF [14, 15,34-36].
hLF1-11, derived from the active N-terminal moiety of 
hLF, has been tested in vitro and in vivo showing broad 
spectrum activity against the pathogens commonly 
involved in infections after HSCT, both bacterial and fun­
gal, similar to hum an lactoferrin. The activity in preclini- 
cal studies was even superior to that of hLF [37]. In vivo 
animal experiments indicated that hLF1-11 is highly effec­
tive against Staphylococcus aureus, Listeria monocytogenes 
and antibiotic resistant Acinetobacter baumannii, reducing 
bacterial loads in  infected organs by 2 to 3 log 
[20,23,24,37]. Furthermore, hLF1-11 was effective against 
invasive infections from fluconazole resistant and fluco­
nazole sensitive Candida species even in  neutropaenic and 
lymphopaenic mice [21,22,38]. Regarding immune-mod­
ulatory properties, as for the antimicrobial activity, the 
activity of hLF1-11 is expected to be similar albeit more 
potent than those reported for hLF, although this has to 
be studied in  more detail.
In this study, for the first time, the antimicrobial peptide 
hLF1-11 has been tested in healthy volunteers and autol­
ogous HSCT recipients. In both populations the drug was
well tolerated with few possibly related side effects. The 
reported events consisted predominantly of discomfort at 
the injection site, commonly reported with intravenous 
drugs. No changes on electrocardiography and in particu­
lar no increase in QT interval was seen. All adverse events 
were mild in  intensity, reversible without clinical sequel, 
not necessitating any intervention. No signs of cytotoxic­
ity were seen, consistent with earlier in vitro data [39], and 
in HSCT recipients no changes in engraftment occurred. 
Pharmacodynamic evaluation revealed no apparent 
changes in  the cytokine profiles, suggesting that the 
immune-modulatory effects of hLF1-11 do not result in 
an unexpected increase in  proinflammatory responses.
During multiple dosing, elevations in  transaminase levels 
were detected and considered related to the study drug in 
five subjects, because use of other drugs or alcohol was 
not allowed during the study, although elevations were 
observed on placebo as well. Similar abnormalities were 
observed in  one patient receiving the 5 mg dose, followed 
by spontaneous and complete recovery. According to the 
CTCv3.0 [26], the maximum elevation was observed once 
in one patient and was moderate (grade 2/3). Since this 
patient was receiving a num ber of other drugs known to 
affect transaminases (Figure 1), this occurred after single
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Table 4: Adverse events in haem atopoietic stem cell 
transplantation (H S C T )  patients (n = 8).
Even t
All recorded events, n 187
All events possibly treatment related, n 4
Events per patient (min to max), n 
Severity (%  of events)
5 to 35
Mild 58
Moderate 25
Severe I7
Non-serious events possibly treatment related, na 4
Supraventricular extrasystoles I
ALT  increased I
AST increased I
y-Glutarate increased I
Serious adverse events (SAEs), nb 4
Heart failure/pulmonary oedema I
Pulmonary infiltrates I
Hypoxaemia/respiratory insufficiency 2
Treatment-related SAEs, n 0
aAll four events occurred in one patient (no. 001); bthe four SAEs 
occurred in two patients (no. 002 and no. 005).
ALT = alanine aminotransferase; AST = aspartate aminotransferase.
dose and no effects on transaminases had been reported 
during single dosing in healthy volunteers but mild eleva­
tions had been recorded after multiple dosing, we consid­
ered this event as possibly related to treatment. A safety 
advisory board (independent of investigators) also evalu­
ated the liver enzyme results of all studies and could not 
establish a definite relationship between hLF1-11 and ele­
vated transaminases, although it did not rule out such an 
effect and advised that a lower dose (0.5 mg) should be 
used in  the next multiple dosing study in  patients, with 
close monitoring of liver parameters. This lower dose is 
expected not to interfere with the antimicrobial activity of 
hLF1-11, shown in preclinical data to be active in the |ig/ 
kg range [22]. Moreover, a recent study emphasised that 
even at very low concentrations AMPs with strong mem­
brane-binding activity could disrupt bacteria by reaching 
higher membrane-bound concentrations than intuitively 
expected [40].
One im portant evaluation that is missing in our studies is 
the pharmacokinetics of hLF1-11, as to date the detection 
of the peptide is impossible to quantify in humans, which 
makes safety evaluations all the more important. Inability
F igure!
Serum  alanine am inotransferase (A L T )  levels in haem atopoietic stem cell transplantation (H S C T ) patients.
The drugs depicted in figure are the drugs used by the patient experiencing elevated transaminases. day 0 = day of haematopoi­
etic stem cell transplantation; HDM = high-dose melphalan.
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to measure hLF1-11 in plasma is partly due to the doses 
being so small (0.005 to 5 mg) that the concentrations in 
plasma are undetectable by usual methods. In animals, 
99mTc-labelled hLF1-11 was rapidly removed from the cir­
culation mainly via the liver and to a lesser extent via the 
kidneys. The quantity of 99mTc-labelled peptide in the 
liver remained stable during the first hour after injection, 
while the plasma half life (in mice) was estimated at 
approximately 30 min, yet this may be a underestimation 
since some of the peptide may be receptor bound and an 
unknown amount may be quickly metabolised. Studies 
are ongoing with internally labelled (C14 and tritium) 
peptide to determine distribution and metabolism in ani­
mals, while the quantification in  humans remains unde­
termined. Nevertheless, the results of this new 
antimicrobial in  preclinical studies merit further investi­
gations on the applicability of hLF1-11 in humans, partic­
ularly in  patients with haematological malignancies, and 
were the motivation for the current studies.
Conclusion
The new antimicrobial drug hLF1-11 was well tolerated in 
healthy volunteers with repeated daily doses up to 5 mg. 
Owing to elevations in  transaminase levels being possibly 
related to treatment caution is warranted in  further stud­
ies, although this potential effect was regarded not clini­
cally serious and reversible without intervention in  all 
cases to date. Nevertheless, as a precaution, further testing 
will be conducted with a lower dose of 0.5 mg in the forth­
coming multiple dosing study in HSCT patients.
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